Yong Mong Bee

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

Carolyn S.P. Lam, Shun Kohsaka, Avraham Karasik et al. · Journal of the American College of Cardiology · 2018 · 466 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Integrated image-based deep learning and language models for primary diabetes care

Jiajia Li, Zhouyu Guan, Jing Wang et al. · Nature Medicine · 2024 · 205 citations · Full text

Nursing, Family Medicine, Health Informatics +17

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD

Eveline Bruinstroop, Rinkoo Dalan, Yang Cao et al. · The Journal of Clinical Endocrinology & Metabolism · 2018 · 110 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Shun Kohsaka, Carolyn S.P. Lam, Dae Jung Kim et al. · The Lancet Diabetes & Endocrinology · 2020 · 93 citations · Full text

Medicine, Cardiology, Pharmacology +12